Table 1.

Current clinical development of COVID-19 vaccines (Adopted form (Pronker et al., 2013)).

S. No.	Therapeutic agents	Properties	Organization/Company	Status
	mRNA-1273	mRNA vaccine	Moderna and NIAID	Phase 2
	BNT162	mRNA vaccine	BioNTech and Pfizer	Phase 1/2
	INO-4800	DNA vaccine	Inovio Pharmaceuticals	Phase 1
	AZD1222	Adenovirus vaccine	University of Oxford and AstraZeneca	Phase 2b/3
	Ad5-nCoV	Adenovirus vaccine	CanSino Biologics	Phase 2
	Unnamed	Inactivated virus	Wuhan Institute of Biological Products and Sinopharm	Phase 1/2
	Unnamed	Inactivated virus	Beijing Institute of Biological Products and Sinopharm	Phase 1/2
	PiCoVacc	Inactivated virus with adjuvant	Sinovac	Phase 1/2
	Unnamed	Inactivated virus	Institute of Medical Biology and Chinese Academy of Medical Sciences	Phase 1
	NVX-CoV2373	Protein subunit	Novavax	Phase 1/2